$XRP $SUI The board of directors of the biopharmaceutical company Acurx Pharmaceuticals, which develops antibiotics for the treatment of bacterial infections, announced plans to acquire $BTC bitcoins for a total of $1 million. The first cryptocurrency will be used as a reserve asset.

President and CEO of Acurx Pharmaceuticals David Lucy stated:

"As demand for bitcoin grows and its acceptance as a primary and key asset class increases, we believe that bitcoin will serve as a powerful reserve asset for funds that will not be needed over the next 12-18 months."

Additionally, he noted that due to its limited supply and resilience to inflation, the first cryptocurrency serves as a reliable store of value. According to Lucy, the approval of a bitcoin ETF and growing support from the government and institutional investors makes the asset "a great addition to the firm's strategy."

The company's CEO emphasized that this initiative does not affect Acurx Pharmaceuticals' overall plans for drug development.